Antitrust: Commission welcomes General Court judgments upholding its Lundbeck decision in first pharma pay-for-delay case

On the 8 September 2016, the General Court fully confirmed the European Commission's findings in its Ludbeck decision. The Commission's found that the Danish pharmaceutical company and four generics competitors had concluded agreements that harmed patients and health care systems. This acting allowed Lundbeck to keep the price of its blockbuster antidepressant medicine citalopram artificially high, which was in breach of Article 101 of the Treaty on the Functioning of the European Union.

ESO: Background information: Antitrust: Commission fines Lundbeck and other pharma companies for delaying market entry of generic medicines http://www.europeansources.info/record/press-release-antitrust-commission-fines-lundbeck-and-other-pharma-companies-for-delaying-market-entry-of-generic-medicines/

---